Innate Pharma SA Basic Earnings Loss Per Share From Continuing Operations
Innate Pharma SA (IPHYF) reported Basic Earnings Loss Per Share From Continuing Operations of -0.55 EUR/shares for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Income Statement › Earnings Per Share
ifrs-full:BasicEarningsLossPerShareFromContinuingOperations · last filed 2026-04-01
| Period end | Basic Earnings Loss Per Share From Continuing Operations 6 month | Basic Earnings Loss Per Share From Continuing Operations 12 month |
|---|---|---|
| 2025-12-31 | -0.55 EUR/shares 20-F · filed 2026-04-01 | |
| 2024-12-31 | -0.61 EUR/shares 20-F · filed 2026-04-01 | |
| 2023-12-31 | -0.09 EUR/shares 20-F · filed 2026-04-01 | |
| 2023-06-30 | 0.02 EUR/shares 6-K · filed 2023-09-14 | |
| 2022-12-31 | -0.73 EUR/shares 20-F · filed 2025-04-30 | |
| 2022-06-30 | 0.08 EUR/shares 6-K · filed 2023-09-14 | |
| 2021-12-31 | -0.57 EUR/shares 20-F · filed 2024-04-04 | |
| 2021-06-30 | -0.22 EUR/shares 6-K · filed 2022-09-15 | |
| 2020-12-31 | -0.01 EUR/shares 20-F · filed 2023-04-06 | |
| 2019-12-31 | 0.12 EUR/shares 20-F · filed 2022-04-04 |